[HTML][HTML] Review of COVID-19 testing and diagnostic methods
O Filchakova, D Dossym, A Ilyas, T Kuanysheva… - Talanta, 2022 - Elsevier
More than six billion tests for COVID-19 has been already performed in the world. The
testing for SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2) virus and …
testing for SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2) virus and …
Viral infection neutralization tests: A focus on severe acute respiratory syndrome‐coronavirus‐2 with implications for convalescent plasma therapy
Viral neutralization tests (VNTs) have long been considered old‐fashioned tricks in the
armamentarium of fundamental virology, with laboratory implementation for a limited array of …
armamentarium of fundamental virology, with laboratory implementation for a limited array of …
[PDF][PDF] Therapeutic activity of an inhaled potent SARS-CoV-2 neutralizing human monoclonal antibody in hamsters
MS Piepenbrink, JG Park, FS Oladunni… - Cell Reports …, 2021 - cell.com
SARS-CoV-2 infection results in viral burden in the respiratory tract, enabling transmission
and leading to substantial lung pathology. The 1212C2 fully human monoclonal antibody …
and leading to substantial lung pathology. The 1212C2 fully human monoclonal antibody …
Generation and Characterization of recombinant SARS-CoV-2 expressing reporter genes
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the
pathogen responsible for coronavirus disease 2019 (COVID-19), has devastated public …
pathogen responsible for coronavirus disease 2019 (COVID-19), has devastated public …
[HTML][HTML] Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452
DG Alleva, AR Delpero, MM Scully, S Murikipudi… - Vaccine, 2021 - Elsevier
AKS-452 is a biologically-engineered vaccine comprising an Fc fusion protein of the SARS-
CoV-2 viral spike protein receptor binding domain antigen (Ag) and human IgG1 Fc …
CoV-2 viral spike protein receptor binding domain antigen (Ag) and human IgG1 Fc …
Potent universal beta-coronavirus therapeutic activity mediated by direct respiratory administration of a Spike S2 domain-specific human neutralizing monoclonal …
Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) marks the third novel β-
coronavirus to cause significant human mortality in the last two decades. Although vaccines …
coronavirus to cause significant human mortality in the last two decades. Although vaccines …
[PDF][PDF] Immunogenicity and protective efficacy of an intranasal live-attenuated vaccine against SARS-CoV-2
Global deployment of an effective and safe vaccine is necessary to curtail the coronavirus
disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 …
disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 …
[HTML][HTML] A randomized phase I/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452
Background Previous interim data from a phase I study of AKS-452, a subunit vaccine
comprising an Fc fusion of the respiratory syndrome coronavirus 2 (SARS-CoV-2) spike …
comprising an Fc fusion of the respiratory syndrome coronavirus 2 (SARS-CoV-2) spike …
Rapid Generation of Circulating and Mucosal Decoy Human ACE2 using mRNA Nanotherapeutics for the Potential Treatment of SARS‐CoV‐2
Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) can cause lethal
pulmonary damage in humans. It contains spike proteins on its envelope that bind to human …
pulmonary damage in humans. It contains spike proteins on its envelope that bind to human …
Modeling SARS-CoV-2 and influenza infections and antiviral treatments in human lung epithelial tissue equivalents
H Zarkoob, A Allué-Guardia, YC Chen… - Communications …, 2022 - nature.com
There is a critical need for physiologically relevant, robust, and ready-to-use in vitro cellular
assay platforms to rapidly model the infectivity of emerging viruses and develop new …
assay platforms to rapidly model the infectivity of emerging viruses and develop new …